Sunshine Technology Co., Ltd
Sunshine Technology Co., Ltd (Sunshine) is an advanced technology company,. Its central focus is researching and developing Zirconium (Hydrogen) Phosphate with superior characteristics and large production capacity. The production base is located in China and company is registered in Australia. According to company’s plan, Research and Production in the wide range of applications of Zirconium Phosphate are arranged. The applications are mainly involved in medical, petrochemical, beauty and other industries. This has led us to create innovative products that provide benefits to every patient around the world. Zirconium phosphate was developed for automated wearable artificial kidney, as a new material, will reduce the treatment cost as a whole, allowing more patients to receive effective treatment at home.
Find locations served, office locations
- Business Type:
- Industry Type:
- Fine Chemicals
- Market Focus:
- Globally (various continents)
- Year Founded:
At present, the specific surface area of each type of Zirconium Phosphate produced is mainly concentrated at 2-3 m2/g, and Zirconium Phosphate is used in many fields such as medical dialysis, chemical, coating, catalysts, antibacterial materials, lubricaing and grease. The company's main customers include: Medtronic, Fresenius, Baxter, and BASF. As a new material manufacturer, Sunshine is based in the global market and seeks to expand and cover a larger market space.
The manufacturing is located in Group 5, Jizhao Village, Mian Yuan Town, Mianzhu City, Sichuan, China, which is an established company with many years of experience. We manufacture all our products in our factory. Our laboratory is continually innovating to provide the highest quality product.
By demonstrating a corporate responsibility towards society we hope to show the true value of our company. Initial estimate shows that, in China, there are two million ESRD(end-stage renal disease) patients，with a yearly increase of 15%，who need regular kidney dialysis treatment. The expected international market is much larger. For hemodialysis, patients need treatment 2-3 times a week, 4 to 4.5 hours each time.